To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Sponsor
Full profile: /officials/B001325
Source: Congress.gov · FEC
Cosponsors (3)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- House Committee on Energy and CommerceReferred To · 2026-06-24
Plain-English Summary
This bill would require doctors to meet with patients in person before prescribing mifepristone (a medication used for abortion) and would limit prescriptions to doctors licensed in the state where the patient lives. The changes would restrict the current ability to prescribe this medication through telehealth or mail, affecting patients seeking medication abortion and the healthcare providers who serve them. The bill is currently under review by a House committee.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- HR9592To authorize the Secretary of State to take certain actions to counter and reduce threats to the space security of the United States, to require the Secretary of State to provide certain consultations to Congress on the space security of the United States, and for other purposes.Referred to Committee · 2026-07-06
- HR9328Improving Travel for Military Members ActReported by Committee · 2026-06-24
- HR8213Defending Women in the Workplace ActReferred to Committee · 2026-04-09
- HR8040No Mercy for Terrorists Act of 2026Referred to Committee · 2026-03-24